Pfizer inc., Pharmaceutical company

New York, June 9 World's first trial, led by an Indian-American doctor, on a mRNA-based vaccine for pancreatic cancer has shown promise for remission.The new shot is developed by BioNTech based on the same technology used by the German biotech company along with its US partner Pfizer to develop vaccines against Covid-19.The groundbreaking trial led by Dr Vinod Balachandran at the Memorial Sloan Kettering Cancer Center (MSK) in New York, showed that half of the patients remained cancer-free 18 months after having their tumours removed and receiving the jabs.The key to these vaccines appears to be proteins in the pancreatic tumours, called neoantigens, which alert the immune system to keep the cancer at bay, according to MSK. The promising results were also presented at the American Society of Clinical Oncology conference in Chicago.In 8 of 16 patients studied, the vaccines activated T cells that recognise the patient's own pancreatic cancers. These patients also showed delayed recurrence of their pancreatic cancers, suggesting the T cells activated by the vaccines may be having the desired effect to keep pancreatic cancers in check.According to Balachandran, mRNA vaccines could stimulate the immune system to recognise and attack pancreatic cancer cells."Unlike some of the other immunotherapies, these mRNA vaccines do appear to have the ability to stimulate immune responses in pancreatic cancer patients," Balachandran said of the promising preliminary results."So we're very excited about that, and the early results suggest that if you have an immune response, you may have a better outcome."Balachandran added the results should be welcome news for other cancer patients too, as pancreatic cancer has been very difficult to treat with traditional chemotherapies and immunotherapies.The phase-I trial was also heralded as "encouraging" by BioNTech."We are committed to taking up this challenge by leveraging our long-standing research in cancer vaccinology and are trying to break new ground in the treatment of such hard-to-treat tumours," BioNTech co-founder and chief medical officer Prof Ozlem Tureci said.A similar trial is also currently underway for bowel cancer – and Moderna, another Covid vaccine manufacturer, is also developing mNRA treatments for cancer and autoimmune conditions.Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Pfizer Inc.FOLLOW

Pfizer inc., Latest News

New York, July 31 Treatment of Covid with Pfizer's antiviral drug Paxlovid, which has shown to cause a ... ...

Washington, July 24 The causative agent for US President Joe Biden's Covid-19 infection is "most likely" the Omicron ... ...

New York, July 20 Although Omicron sub-variants have evolved to evade antibody responses from the primary Covid vaccine ... ...

Los Angeles, July 16 The BA.5 Omicron subvariant, now the dominant coronavirus strain in the US, is four ... ...

Those with systemic lupus erythematosus, or SLE, who received a "booster" dose of the SARS-CoV-2 vaccine after receiving the full dosage are about half as likely to experience a subsequent "breakthrough" COVID-19 infection, according to a recent stud ...

Doha, June 17 People with prior-variant infection were moderately protected from Omicron even after a year, but vaccine-induced ... ...

New York, June 12 Inactivated and mRNA Covid-19 vaccines appear to be safe for patients treated for hypothyroidism, ... ...

New York, June 9 World's first trial, led by an Indian-American doctor, on a mRNA-based vaccine for pancreatic ... ...